November 2020 in “Journal of The American Academy of Dermatology” Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
14 citations,
October 2016 in “Psychoneuroendocrinology” Finasteride affects brain processes related to neurotransmission and metabolism, potentially helping with neuropsychiatric conditions.
May 2023 in “The Journal of Sexual Medicine” Men with self-diagnosed PFS-related ED have normal erectile hemodynamics.
The paper suggests that a decrease in estrogen receptor activity may cause sexual dysfunction syndromes and proposes hormonal treatments.
2 citations,
July 2021 in “The Journal of Sexual Medicine” Gene expression differences in PFS patients suggest a potential organic cause for symptoms.
May 2016 in “The Journal of Sexual Medicine” Younger people (median age 35) experience more PFS-like symptoms with 1mg finasteride; more research needed.
30 citations,
January 2020 in “Fertility and Sterility” Finasteride can cause serious side effects in some men, needing more research for treatment.
16 citations,
December 2014 in “International Journal of Biological Markers” Longer CAG and GGN repeats increase alopecia risk, but no significant link to post-finasteride syndrome found.
15 citations,
March 2020 in “Anais Brasileiros De Dermatologia” Finasteride may cause lasting sexual, mental, and physical symptoms; use with caution.
8 citations,
October 2021 in “The international journal of risk and safety in medicine” The document sets criteria for diagnosing long-term sexual dysfunctions caused by certain medications.
8 citations,
July 2018 in “Current Sexual Health Reports” Finasteride can cause lasting sexual dysfunction, depression, and other side effects, needing more research for treatment.
8 citations,
January 2016 in “Indian Journal of Pharmacology” Finasteride and dutasteride can cause severe, lasting side effects.
Finasteride may cause changes in dopamine-related genes, possibly leading to post-finasteride syndrome.
September 2011 in “Urology” Biofeedback treatment for dysfunctional voiding in adults showed no symptom improvement.
January 2022 in “Archivos españoles de urología” Post-finasteride syndrome is rarely linked to sexual and systemic side effects.
May 2021 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Clinicians need to better understand and treat Post-finasteride syndrome.
Finasteride use is linked to a higher risk of obstructive sleep apnea.
Finasteride use is linked to a higher risk of obstructive sleep apnea.
January 2020 in “Archives of urology” Finasteride, a drug used for certain conditions, can cause serious side effects like sexual dysfunction, suicidal thoughts, and increased diabetes risk, and there's a need for more awareness and research about these effects.
July 2018 in “Reactions Weekly” Lower finasteride doses had more side effects; dutasteride caused back pain; more research needed on post-finasteride syndrome.
March 2017 in “European Urology Supplements” Gene differences affect finasteride side effects in men with hair loss.
June 2024 in “Trends in Urology & Men s Health” Post-finasteride syndrome is rare but serious and should be taken seriously.
October 2024 in “Journal of the Endocrine Society” Post-finasteride syndrome can cause lasting sexual, physical, and mental health issues with limited treatment options.
July 2020 in “Vestnik urologii” The cause of post-finasteride syndrome is unclear and needs more research.
September 2011 in “Urology” Some patients fail bladder function tests due to lower flow rates and higher remaining urine volumes, but the exact reasons for failure are unclear.
April 2020 in “The FASEB Journal” Finasteride may cause lasting sexual issues by altering specific genes in human cells.
June 2024 in “Journal of Clinical Oncology” The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
February 2012 in “European Urology Supplements” Finasteride for hair loss may cause long-lasting sexual side effects in young males.
9 citations,
February 2012 in “Cancer Chemotherapy and Pharmacology” The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.
4 citations,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.